|
Pamiparib Clinical Trials
2 actively recruiting trials across 1 location
Also known as: BGB-290
Pipeline
Phase 1: 1Phase 2: 1
Top Sponsors
- University of Chicago1
- The First Affiliated Hospital of Xiamen University1
Indications
- Cancer2
- Head and Neck Cancer Stage IV1
- Head and Neck Cancers - Throat1
- Locally Advanced Prostate Cancer1
- Oligometastatic Prostate Cancer1
Other1 trial
Chicago, Illinois1 trial
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
The University of Chicago
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.